H.R. 8205 House Health
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
STAGE 4 OF 8 — HOUSE FLOOR
Currently in the House. Last action: motion to reconsider laid on the table agreed to without objection on Jul 22, 2026.
- House Introduced in House Apr 6, 2026
- House Referred to the House Committee on Energy and Commerce. Apr 6, 2026
- House Referred to the Subcommittee on Health. Apr 6, 2026
- House Subcommittee Consideration and Mark-up Session Held May 13, 2026
- House Forwarded by Subcommittee to Full Committee by Voice Vote. May 13, 2026
- House Committee Consideration and Mark-up Session Held May 21, 2026
- House Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0. May 21, 2026
- House Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733. Jul 9, 2026
- House Placed on the Union Calendar, Calendar No. 637. Jul 9, 2026
- House Mr. Guthrie moved to suspend the rules and pass the bill, as amended. Jul 20, 2026
- House Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653) Jul 20, 2026
- House DEBATE - The House proceeded with forty minutes of debate on H.R. 8205. Jul 20, 2026
- House At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn. Jul 20, 2026
- House Considered as unfinished business. Jul 22, 2026
- House Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Jul 22, 2026
- House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Jul 22, 2026
- House Motion to reconsider laid on the table Agreed to without objection. Jul 22, 2026
Cosponsors
103
Subjects
Department of Health and Human ServicesDrug therapyFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingInternet, web applications, social mediaMedical researchNational Institutes of Health (NIH)Neurological disordersPublic-private cooperationResearch administration and funding
Committees
- Energy and Commerce Committee
- [Reported By, Jul 9, 2026]
- [Markup By, May 21, 2026]
- [Referred To, Apr 6, 2026]
Summary
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.The bill reauthorizesgrants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, anda Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
[Summary as of: Reported to House]
Comments · 0
Please log in to post a comment.
Loading comments...